Form D · Private Equity Fund

Redmile Biopharma Investments I, L.P.

San Francisco, CA · CIK 0001649327

Offering snapshot reported Jul 27, 2018 · SEC filing

Reported sold: $218M
Investors reported: 87
Minimum accepted: $0
First sale: Jul 28, 2015

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$77,205,213 → $218,270,000
Reported investors24 → 87

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jul 27, 2018	Amendment	$218,270,000	$141,064,787vs Jul 28, 2017	87	SEC filing
Jul 28, 2017	Amendment	$77,205,213	$47,205,213vs Jul 28, 2016	24	SEC filing
Jul 28, 2016	Amendment	$30,000,000	No comparison	3	SEC filing
Jul 28, 2015	Initial	Yet to sell	No comparison	0	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.1, 3C.7
Duration over one year: No
Business combination: No

Sales commissions: $103K
Finders' fees: $0
Form D file number: 021-244604

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Hollister Associates, LLC	173366	Hollister Associates, LLC · CRD 173366

Source: Form D, filed Jul 27, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

REDMILE BIOPHARMA INVESTMENTS I, L.P.

Investment adviser: REDMILE GROUP, LLC

Gross asset value: $145M
Beneficial owners: 82
ADV minimum commitment: $2M

Reported in Form ADV on Aug 28, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator ALTER DOMUS (US) LLC CHICAGO, Illinois, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor ERNST & YOUNG LLP SAN FRANCISCO, California, United States

Custodian FIRST-CITIZENS BANK & TRUST COMPANY PALO ALTO, California, United States Related to adviser: No

Custodian JP MORGAN CHASE BANK, N.A. NEW YORK, New York, United States Related to adviser: No

Custodian MORGAN STANLEY & CO. LLC SAN FRANCISCO, California, United States Related to adviser: No

Prime broker MORGAN STANLEY & CO. LLC SAN FRANCISCO, California, United States

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: No

ERNST & YOUNG LLP
PCAOB 42

FIRST-CITIZENS BANK & TRUST COMPANY
LEI L9VVX1KT5TFTKS0MLF66

JP MORGAN CHASE BANK, N.A.
LEI 7H6GLXDRUGQFU57RNE97

MORGAN STANLEY & CO. LLC
SEC 8-15869

MORGAN STANLEY & CO. LLC
CRD 8209 · SEC 8-15869

Filing source

Form ADV 2125340 · Aug 28, 2026 · Schedule D 7.B.(1), fund 805-3847972073

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Jonathan Forman	Promoter
Jeremy Green	Promoter
Mike Lee	Promoter
Amrit Nagpal	Promoter
N/A N/A Redmile Biopharma Investments I (Gp), Llc	Promoter
General Partner Redmile Biopharma Investments I (Gp), Llc	Promoter
N/A N/A Redmile Biotechnologies Investments I (Gp), Llc	Promoter
N/A N/A Redmile Group, Llc	Promoter
Managing Mbr Of The Gp Of The Issuer Redmile Group, Llc	Promoter

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

One Letterman Drive, Building D Suite D3 300
San Francisco, CA, 94129